SCHEMBL2284331

SCHEMBL2284331

NCc1ccc(-c2nc3ccn4c(-c5cc(C(F)(F)F)n[nH]5)nnc4c3cc2-c2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 15/20 0.42
AKT2 P31751 15/20 0.42
KCNH2 Q12809 5/20 0.42
AKT3 Q9Y243 2/20 0.42
FECH P22830 1/20 0.42
NPBWR1 P48145 1/20 0.31
SGK1 O00141 1/20 0.31
ADORA2A P29274 2/20 0.31
ADORA2B P29275 1/20 0.31
DHODH Q02127 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279557 0.88 AKT1 (0.46) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2286258 0.83 AKT1 (0.46) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2279260 0.82 AKT1 (0.44) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2279134 0.81 AKT1 (0.45) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2279232 0.81 AKT1 (0.43) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2286818 0.81 AKT1 (0.48) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2279608 0.81 AKT1 (0.41) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2279628 0.81 AKT1 (0.46) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2280962 0.80 AKT1 (0.47) AKT1AKT2KCNH2AKT3FECH
SCHEMBL2282352 0.80 AKT1 (0.44) AKT1AKT2KCNH2AKT3FECH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1898903-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2013-03-27 EP claimed
US-8008317-B2 Inhibitors of akt activtiy MERCK SHARP & DOHME CORP. (US) 2011-08-30 US claimed
US-20100222321-A1 Inhibitors of akt activtiy MERCK SHARP & DOHME LLC 2010-09-02 US claimed
EP-1898903-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2013-03-27 EP disclosed
EP-1898903-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2013-03-27 EP disclosed
US-8008317-B2 Inhibitors of akt activtiy MERCK SHARP & DOHME CORP. (US) 2011-08-30 US disclosed
US-8008317-B2 Inhibitors of akt activtiy MERCK SHARP & DOHME CORP. (US) 2011-08-30 US disclosed
US-8008317-B2 Inhibitors of akt activtiy MERCK SHARP & DOHME CORP. (US) 2011-08-30 US disclosed
US-20100222321-A1 Inhibitors of akt activtiy MERCK SHARP & DOHME LLC 2010-09-02 US disclosed
US-20100222321-A1 Inhibitors of akt activtiy MERCK SHARP & DOHME LLC 2010-09-02 US disclosed
US-20100222321-A1 Inhibitors of akt activtiy MERCK SHARP & DOHME LLC 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222321-A1 Inhibitors of akt activtiy PIK3CA, PIK3CD, INPP5D AKT1 8/4885AKT2 4/4885KCNH2 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.